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LING ZHI-8: STUDIES OF A NEW IMMUNOMODULATING AGENT
L ieu w e G . van  d e r Hem ,1,2 J .  Adam van  d e r V lie t ,1 C. F ra n s  M . B o c k e n ,1 K o h su k e  K in o ,3
A n d rie s  J .  H o itsm a ,4 and  W i l  J.M . Tax4
Department of Surgery and Department of Medicine, Division of Nephrology, University Hospital Nijmegen Nijmegen,
The Netherlands, and Biochemical Genetics Division, Meiji Institute o f Health Science, Odawara, Japan
Ling Zhi-8 (LZ-8) is a protein derived from the fun­
gus Ganoderma lucidum and has immunomodulatory 
capacities. It was shown to be mitogenic toward mouse 
splenocytes in vitro and immunosuppressive in vivo 
by reducing antigen-induced antibody formation and 
by preventing completely the incidence of autoim­
mune diabetes in nonobese diabetic mice. In this 
study, the mitogenic effects of LZ-8 on human mono­
nuclear cells are reported. In accordance to its mito­
genic effect on mouse splenocytes, LZ-8 proved to be 
mitogenic for human PBMC. This mitogenic effect of 
LZ-8 apparently required the presence of monocytes. 
We also demonstrated it to be immunosuppressive in 
vitro in a human MLC performed in the absence of 
monocytes, using purified T cells and EBV-trans- 
formed allogeneic B cells. Furthermore, we tested LZ-8 
for its possible suppressive effects in 2 different mod­
els of allogeneic tissue transplantation. LZ-8 proved to 
have a significant effect on cellular immunity, since its 
administration in an allografted mouse skin model re­
sulted in an increased survival time. In a model of 
transplanted allogeneic pancreatic rat islets, LZ-8 was 
effective in delaying the rejection process of al­
lografted islets. More frequent or continuous adminis­
tration resulted in a further prolongation of survival 
time. No serious side effects of LZ-8 could be discerned 
in these experiments.
The first report on a new immunosuppressive agent, Ling- 
Zhi 8 (LZ-8*), was published by Kino and associates (1) in 
1989. It concerned a purified protein with a molecular mass 
of 13-17 kDa that had been isolated from the fungus Gano­
derma lucidum, The complete amino acid sequence of LZ-8 
C2) and the nucleotide sequence (3) were determined subse­
quently. The LZ-8 molecule consists of a homo dimer of 2 
polypeptides of 110 amino acids, which bear primary and 
secondary structural similarities with the immunoglobulin 
heavy chain. This led to the hypothesis that LZ-8 might be an 
ancestral protein of the immunoglobulins (2),
In vitro, LZ-8 was mitogenic for mouse splenocytes (1). The 
immunomodulatory activity of LZ-8 in vivo was explored by 
determination of its effect on systemic anaphylaxis and on 
the Arthus reaction in CFW mice. A complete prevention of 
systemic anaphylactic reactions occurred and a 45% decrease
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in the incidence of Arthus reactions was observed (I). The 
ability of LZ-8 to suppress the production of specific antibody 
was demonstrated in C57B110 mice. A 80-95% decrease of 
antibody production to HBsAg was observed in the LZ-8- 
treated animals (4\ LZ-8 injections in young female nonobese 
diabetic (NOD) mice completely prevented the occurrence of 
autoimmune diabetes mellitus in these mice, whereas in a 
control group of female NOD mice, the incidence of diabetes 
mellitus was 70% after 40 weeks of age (5). Histological 
examination of pancreatic islets in both groups revealed only 
slight insulitis in LZ-8-treated mice, whereas control islets 
showed massive lymphocytic infiltration. LZ-8 was immuno­
suppressive without having severe concomitant toxic effects 
on pancreatic islets. This might be in contrast to other im­
munosuppressive agents, since prednisone (6, 7), CsA (8, 9)t 
and more recently developed agents, such as FK506 (9, 10), 
all show toxic side effects on pancreatic islets.
In the present report, we evaluated the effects of LZ-8 
administration on survival of allogeneically transplanted 
pancreatic islets in rats. The immunomodulating effects of 
LZ-8 were also studied in a mouse skin allograft model. In 
addition, the mitogenic and immunosuppressive effects of 
LZ-8 on human mononuclear cells in vitro were investigated 
and we demonstrate that LZ-8 can suppress the allogeneic 
response of human T lymphocytes in vitro.
MATERIALS AND METHODS
Drug. Purified LZ-8 was obtained from the Meiji Institute of 
Health Science, Odawara, Japan. The agent was purified from 
G lucidum mycelia by gel filtration, followed by ion exchange chro­
matography, as described previously {I). The purified protein is 
dissolved in PBS in a concentration of 1 mg/ml. It was partly further 
concentrated for the transplantation experiments in rats using an 
Amicon YM10 filter to reach a final concentration of B mg/ml. The 
LZ-8 solution was kept frozen at — 20°C until use.
Cells. Samples of human peripheral mononuclear cells (MNC), 
T lymphocytes, and EBV-transformed B lymphocytes were obtained 
from healthy volunteers. Cells were procured and stored in a previ­
ously described manner (11),
T  lymphocytes. Lymphocytes were purified from peripheral MNC 
by counterflow centrifugation. T lymphocytes were isolated from this 
suspension by rosetting with sheep erythrocytes treated with amino- 
ethylisothiouronium bromide. The purified T lymphocytes were cryo- 
preserved,
EBV-transformed B lymphocytes. Cry op reserved MNC from some 
individuals were used for EBV transformation of the B cells. Immor­
talization and stabilization of the cell lines was performed by Dr. F. 
Uytdehaag and co-workers at the Department for Public Health 
(RIVM) at Bilthoven, The Netherlands. EBV-transformed B cell lines 
were cultured in RPMI1640 medium containing HEPES and sodium 
bicarbonate, supplemented with 10% heat-inactivated PCS, 2 mM 
glutamine, 1 mM sodium pyruvate, and gentamycin (40 /xg/ml). Only 
cells negative for Mycoplasma were used in the present study.
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Mitogenic activity of LZ-8. Mitogenic activity of LZ-8 was deter­
mined with 3 different final concentrations of LZ-8 (0,1, 1, and X0 
/xg/ml). LZ-8 was incubated with either MNC or purified T cells. Each 
well contained 2 x l 0 5 cells in RPMI 1640 Dutch modification me­
dium (ICN Biomedicals, Costa Mesa, CA) containing 10% heat-inac­
tivated FCS (Gibco, Life Technologies, Breda, The Netherlands), 2 
mM glutamine, 1 mM sodium pyruvate, and gentamycin (40 /xg/ml) 
in a final volume of 100 ¡xl. All incubations were performed in 
triplicate in U-bottom plates (Costar, Cambridge, MA) in a humidi­
fied environment at 37°C and 5% C02. Sixteen hours before mea­
surement of mitogenic activity, 50 ¡x\ of [3H]thymidine (0.5 ¿iCi/well; 
Amersham International, Amersham, UK) were added. Thymidine 
incorporation was measured using a cell harvester and a Betaplate 
liquid scintillation counter (Pharmacia, Uppsala, Sweden). The mi­
togenic activity of LZ-8 was determined after 3, 4, 5, 6, and 7 days of 
incubation. In additional experiments, the mitogenic effect of LZ-8 
after 3 days of incubation was measured in the complete absence of 
FCS. In these experiments, 10% autologous serum was present in­
stead.
Immunosuppressive activity of LZ-8 in vitro, MLC were per­
formed by incubation of human peripheral MNC obtained from 2 
unrelated donors (105 responder cells plus 105 stimulator cells). Cells 
were obtained from the same donors as were used for the study on 
mitogenic activity of LZ-8. Stimulator cells were irradiated with 60 
G y 'In a second series of experiments, 2 x10s T cells were incubated 
with 4X104 irradiated (60 Gy) allogeneic EBV-B cells. T lymphocytes 
from 2 different donors were used. LZ-8 solution was added in 3 
different final concentrations: 0.1, 1, and 10 ¿ig/ml. After 6 days, 50 
/xl of [3H]thymidine were added to each well and 16 hr later, thymi­
dine incorporation was measured with a cell harvester and a Beta­
plate liquid scintillation counter.
Mouse skiji transplantation. B10.D2 mice (H2d, Olac, Bicester, 
Great Britain) weighing 20-25 g served as skin donors and C57B110 
mice (H2b, University Animal Facilities, Nijmegen, The Nether­
lands) served as recipients. These 2 mice strains have the same 
non-MHC background, but are completely mismatched with respect 
to their MHC alleles.
Full-thickness skin flaps were procured from tails of donor mice. A 
patch of donor skin was attached by adhesive wound spray to the 
flank of recipients after removal of a corresponding skin area. All 
transplanted sites were checked for signs of rejection on a daily basis. 
This was considered to have occurred on the day that complete 
necrosis of the transplanted skin was recorded. Skin transplanta­
tions were performed in 3 different groups and 2 different regimens 
of LZ-8 administration were applied after transplantation. Group 1 
(controls, n=12) received an intraperitoneal saline injection of 0.3 ml 
twice a week after transplantation. Group 2 (n-11) had an intraper­
itoneal injection of 0.3 ml of a 1-mg/ml LZ-8 solution (15 mg/kg) twice 
a week after transplantation. An intraperitoneal injection of 0.3 ml of 
a 0.5-mg/ml LZ-8 solution (7.5 mg/kg) was administered 4 times a 
week to group 3 (n=12) after skin transplantation.
Rat pancreatic islet transplantation. Male Lewis rats (RT11) 
weighing 250-300 g were obtained from the University Animal Fa­
cilities, Nijmegen, The Netherlands, and served as islet donors. Male 
F344 rats (RTllv) with a weight of 250-300 g were obtained from 
Charles River Wiga, Sulzfeld, Germany, and were the recipients of 
islet transplants. Recipients were rendered diabetic with an injection 
of 30 mg/kg streptozotocin (Sigma Chemicals, St. Louis, MO) into the 
penile vein 1 week before transplantation. They were considered to 
be diabetic with nonfasting blood glucose levels above 20 mmol/L, as 
measured with a Reflolux glucose analyzer (Boehringer Mannheim, 
Germany).
Pancreatic islets were obtained according to a previously de­
scribed method, with some modifications (12). Donor pancreases 
were distended by an intraductal injection of 15 ml of a cold HBSS 
(Gibco, Life Technologies) containing 1 mg/ml collagenase (Collage- 
nase P, Boehringer Mannheim, intrinsic activity 1.58 Wünsch
U/mg). After a pancreatectomy, the gland was incubated in a sta­
tionary water bath, followed by a mechanical dissociation with fil­
tering through a nylon filter (pore size of 800 jam) and centrifugation 
on a Dextran gradient (Sigma, m.w. 70.000, industrial grade, density 
stock solution: 1.094 g/ml). The discontinuous gradient was com­
pleted by adding layers of 1.081 g/ml, and 1.041 g/ml on top. Gradi­
ents were centrifuged at 4 0 for 4 min and 500X£ for 12 min. Islets 
were harvested at the topmost interface. After 2 more washes with 
HBSS, the islets of 2 donors were suspended in 2.5 ml of HBSS.
Diabetic recipients were anesthetized with ether and underwent a 
laparotomy. A 23-gauge butterfly needle was used to inject the islets 
in a mesenteric vein. Hemostasis was assured by hemostatic clips 
(LS100, Ethicon, Norderstedt, Germany).
After surgery, nonfasting blood glucose levels were determined on 
a daily basis with the Reflolux glucose analyzer. Rejection of trans­
planted islets was considered to have occurred on the first of 3 
consecutive days with a blood glucose Srll mmol/L.
Pancreatic islet transplants were performed in 4 different groups. 
Group A (n=9) received an allogeneic islet transplantation on day 0 
without concomitant immunosuppression. Group B (n=6 ) had an 
intraperitoneal injection of 15 mg/kg LZ-8 twice every week after 
transplantation until the day of rejection. A daily intraperitoneal 
injection of 5 mg/kg LZ-8 was given to group C (n=6) after islet 
transplantation until rejection occurred. The effects of continuous 
intraperitoneal immunosuppression were studied in 8 other animals 
(group D). In this group, an osmotic minipump (2 ML1, Alzet, Palo 
Alto, CA) with a reservoir volume of 2 ml and an operational period 
of 7 days was filled with LZ-8 (5 mg/ml) during transplantation and 
inserted in the abdominal cavity. This dosage is an equivalent of 
nearly 6 mg/kg/day LZ-8 . These pumps drained freely in the abdo­
men. Osmotic minipumps were removed 3 weeks after implantation 
in persistent normoglycemic animals. Cumulative week doses of 
LZ-8 were 30 mg/kg body weight in group B, 35 mg/kg body weight in 
group C, and 40 mg/kg in group D. Body weights were measured on 
a daily basis in all animals. Nutritional status and possible hepato- 
toxic or nephrotoxic effects were evaluated by measuring serum total 
protein, albumin, liver enzymes, and creatinine.
Animals were killed either after a return to the hyperglycemic 
state, or after 28 days, which was considered to be a long-term 
function in this experiment. The liver and native pancreas were 
excised for histological examination. Specimens of the liver were 
checked for the presence of pancreatic islets and lymphocytic infil­
tration by immunoperoxidase and hemotoxylin-eosin staining.
Statistics. For statistical analysis of data on mitogenic and sup- 
pressive activity of LZ-8 and of survival data, a Wilcoxon rank sum 
test was used throughout this study. For analysis of weight loss in 
LZ-8-treated groups, a one-tailed Student’s t test was used. P-values 
less than 0.05 were considered to be significant.
RESULTS
Mitogenic activity of LZ-8, When human MNC (obtained 
from 6 unrelated individuals) were incubated with LZ-8, a 
strong mitogenic response was measured in all cases. Peak 
activity of LZ-8-stimulated mitogenesis was observed after 3 
days of incubation of human MNC with LZ-8 at all concen­
trations tested (Fig. 1, P<0.01 for LZ-8-treated groups vs. 
controls). The highest mitogenic activity was observed with 1 
/ng/ml LZ-8 after 3 and 4 days of incubation (P<0.05 for 1 
;/ml LZ-8 vs. other LZ-8-treated groups). The stimulatory 
effect of LZ-8 decreased rapidly over time. After an incuba­
tion time exceeding 4 days, LZ-8 no longer induced a signif­
icant increase of [3H]thymidine incorporation. In contrast to 
the results of MNC, the incubation of purified T lymphocytes 
with LZ-8 hardly resulted in any thymidine incorporation 
(Fig. 2, note the different scale on the y axis). Only incubation 
with 10 fig/ml LZ-8 resulted in some T cell activation (P<0.05
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F igure 1, Proliferation of human MNC with different LZ-8 concen­
trations (mean value ± SD) after increasing incubation times (3-7 
days) (*P<0.01 vs. controls).
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F igure 2. Proliferation of human T cells with different LZ-8 concen­
trations (mean value ± SD) after increasing incubation times (3-7 
days) (*P<0.05 vs. controls).
vs. controls and vs. other LZ-8 concentrations), but the values 
obtained were much lower than those obtained in the pres­
ence of monocytes. LZ-8 was also mitogenic for MNC when 
autologous serum was used instead of FCS. In a comparative 
experiment, the mitogenic effect of LZ-8 (1 ¡igfml) in both 
types of serum was similar (25,099±2,610 and 22,571± 1,845 
cpm), whereas background values were lower in autologous 
serum (176±58 and 1,602±257 cpm).
Immunosuppressive activity of LZ-8. When MNC were 
used to perform an MLC, the addition of LZ-8 resulted in an 
increased proliferation of the responder cells with all concen­
trations of LZ-8, reflecting the mitogenic activity of LZ-8 
(data not shown).
A high level of T cell activation could also be obtained
when purified T cells were incubated with irradiated alloge­
neic EBV-B cells. In such an MLC in the absence of mono­
cytes, LZ-8 was able to inhibit MLC activity significantly 
(Fig. 3). In a representative experiment, incubation of T cells 
with allogeneic EBV-B cells resulted in [3H]thymidine incor­
poration of 134,398±5,144 cpm (mean of triplicate results ± 
SD). With 0.1 ju,g/ml LZ-8, 78,001±2,485 cpm were measured 
(a mean inhibition of 42%). Addition of 1 /xg/ml and 10 /¿g/ml 
LZ-8 resulted in 63,141 ±5,408 cpm (53% inhibition) and 
45,365±7,136 cpm (66% inhibition), respectively (P all LZ-8 
concentrations vs. controls < 0.01). Similar results were ob­
tained in 5 additional MLC experiments using T cells and 
allogeneic EBV-transformed B cells.
Mouse skin transplantation. Group 1 (saline injections) 
showed a mean survival time (MST) ± SD of 10.2±1.1 days 
(Table 1). Group 2, which received LZ-8 twice weekly, dem­
onstrated an MST of 11.5±1.8 days (group 2 vs. group 1; 
P=0.06). Group 3 (LZ-8 injections 4 times a week) showed a 
prolonged survival time of 13.3±2.9 days (group 3 vs. group 
1; P<0.01, and group 3 vs, group 2: NS). No animals showed 
any adverse effect of LZ-8 administration and weight incre­
ment during the experiment was the same as in controls.
Eat pancreatic islet transplantation. Control animals 
(group A) showed a rejection of their islet grafts after 
4.7±0.15 days (Fig. 4). On the day of rejection, blood sugars 
had nearly tripled, compared with the previous day. Treat­
ment with LZ-8 resulted in markedly prolonged graft sur­
vival (Table 2). MST ± SD of allografted islets in group B was 
9.7±0.8 days (group B vs. group A: P<0.01). Daily LZ-8 
administration in group C resulted in an MST ± SD of 
11.0±0.7 days (group C vs, group A: P< 0.001, group C vs. 
group B: NS). Continuous intraperitoneal immunosuppres­
sion with 5 mg/ml LZ-8 for a period of 7 days (group D) 
prolonged allograft survival until 12.5± 1.2 days (group D vs. 
group A: PcO.OOl, group D vs, group B: P<0.05, and group D 
vs. group C: NS). All animals remained normoglycemic (non­
fasting blood glucose <11 mM) during the delivery period of 
the osmotic pumps. Body weights in group B increased 9.8% 
overall during the first 8 postoperative days. Weight increase 
was not significantly different from that of allograft controls
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F igure 3. Suppressive activity of different LZ-8 concentrations in 
an MLC of human T cells and irradiated allogeneic EBV-B cells. 
Data from a representative experiment are shown; similar results 
were obtained in 6 additional experiments.
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Table 1. MST ± SD of allogeneic skin transplants from B10D2 
mice (H2d) to C57B110 mice (H2b) in LZ-8-treated groups
1.1-
Treatment MST(days) P
Group 1 0.3 ml i.p. saline 10.2± 1,1
(n=12) 2 X/week
Group 2 15 mg/kg LZ-8 i.p. 11.5 + 1.8 1 vs. 2: 0.06
(n=12) 2x/week
Group 3 7.5 mg/kg LZ-8 i.p. 13.3±2.9 1 vs. 3: <0.01
(n=l l ) 4 X/week 2 vs. 3: NS
Blood glucose 
(mM)
30-
--Ù---
Controls
(n=9)
LZ-B15 mg/kg 2x/week 
(n=6)
LZ-8 5 mg/kg dally 
(n=B)
LZ-8 continuous 
(n=6)
/ p-d' A
p)!
Ì';
rê-5'ô "ô';'Q
À0/
-/
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T
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- r12 t14
~T~
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Days
F ig u re  4. Mean nonfasting blood glucose levels (mM) after pancre­
atic islet transplantation from Lewis to F344 rats in control animals 
and in groups treated with different LZ-8 re g im e n B  ( 1 5  mg/kg twice 
a week, 5 mg/kg daily, and 5 mg/kg continuously). Rejection of islet 
grafts is supposed to have occurred in animals with blood glucose 
>11 mM.
T a b le  2. MST ± SD of allogeneic pancreatic islets from Lewis 
rats (RT11) to diabetic F344 rats (RTllv) in LZ-8-treated groups
Treatment MST(days)
Group A Control group 4.7±0.2
(n=9)
Group B 15 mg/kg LZ-8 i.p. 9.7±0.8 A vs. B: <0.01
(n=6) 2 X/week
Group C 5 mg/kg LZ-8 i.p. 11.0±0.7 A vs. C: < 0,01
( n - 6) daily
Group D 5 mg/kg LZ-8 12.5±1.2 A vs. D: <0.01
(n=6) continuous B vs. D: <0.05 
C vs. D: NS
during their normoglycemic period. In both groups C and D, 
significant weight loss was noticed during the first postoper­
ative days, compared with controls and group B (Fig. 5) 
(P<0.05 vs. controls).
The nutritional status of animals was not jeopardized by 
LZ-8, since serum albumin and total serum protein ranged 
between 22-31 g/L and 50-65 g/L, respectively, with no 
differences among groups. Also liver enzyme and serum cre­
atinine levels were all in the normal range.
Relative weight
1.05-
LZ-8 5 mg/kg U LZ-8 15 mg/kg
LZ-8 continuous — - o — Controls — A—
O' .... ..
0.95-
Days
Figure 5, Mean relative weights of different LZ-8-treated groups 
after rat allogeneic islet transplantation, compared with mean pre­
operative weights of each group (*P<0.05 vs. controls).
Histological examination of samples of liver tissue in nor­
moglycemic LZ-8-treated animals revealed the presence of 
well-preserved islets, surrounded by normal liver paren­
chyma. In normoglycemic animals, only small cellular infil­
trates could be detected. Immunoperoxidase staining for in­
sulin was evidently positive in the intrahepaticaliy 
transplanted islets.
DISCUSSION
This study addresses the immunomodulatory properties of 
LZ-8 in in vitro and in vivo conditions. LZ-8 proves to be a 
potent mitogen for human MNC. This mitogenic effect on 
human MNC is in accordance with the results obtained with 
murine splenocytes (1). The maximal [3H]thymidine incorpo­
ration in NOD murine lymphocytes occurred at an LZ-8 con­
centration of 1.56 fjiglml. Also in our experiment, [3H]thymi­
dine incorporation at 1 /¿g/ml LZ-8 was significantly higher 
than at 0.1 or 10 /xg/ml, This mitogenic effect turned out to be 
limited in time, as after 4 days of incubation only background 
stimulation was recorded, irrespective of the concentration of 
LZ-8. The mitogenic effect of LZ-8 requires monocytes as 
accessory cells, since purified T lymphocytes were not acti­
vated by LZ-8. When autologous serum was used instead of 
FCS, a similar mitogenic response to LZ-8 was measured. 
This finding indicates that FCS is not involved in the ob­
served mitogenic effect of LZ-8, and furthermore suggests 
that Fc receptors (which will be blocked by the immunoglob­
ulin present in autologous serum) are not required for this 
mitogenic effect.
The observed mitogenic response of LZ-8 on human MNC 
overruled possible immunosuppressive effects of LZ-8 in an 
MLC, since no suppressive effect by LZ-8 could be measured 
after 6 days in an MLC of human MNC and results obtained 
were actually higher with LZ-8. Therefore, we modified the 
MLC by using EBV-B cells as stimulator cells and tested the 
proliferative response of purified human T cells in the ab­
sence of monocytes. In this experiment, an evident immuno­
suppressive effect of LZ-8 was demonstrated. [3H]Thymidine
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incorporation was inhibited around 40% by 1 ju,g/ml LZ-8 and 
even stronger inhibition (60%) of T cell activation was noticed 
with a concentration of 10 /xg/ml LZ-8. This is the first dem­
onstration of in vitro inhibition of an allogeneic response by 
LZ-8. Pretreatment of DBA/2 mice with LZ-8 in vivo before 
the isolation of splenocytes used for MLC also resulted in a 
decreased MLC. In this model, inhibition was observed both 
at the level of the responder cells and at the level of stimu­
lator cells (K. Kino, Meiji Institute of Health Science, per­
sonal communication, 1992).
It is remarkable that LZ-8 can induce in vitro both prolif­
eration of MNC and inhibition of the allogeneic response ofT 
cells. The inhibitory effect of LZ-8 is consistent with its im­
munosuppressive effect in vivo, which was reported previ­
ously (4,5) and confirmed by the present data. The mitogenic 
effect of LZ-8 may seem paradoxical in this respect, but 
similar in vitro results (inhibition of T cell function as well as 
mitogenic activity) have been obtained with anti-CD3 anti­
bodies that are immunosuppressive in vivo.
The relatively small increase in graft survival seen in our 
allogeneic mouse skin model may seem slightly disappointing 
when compared with the results reported by Kino, His group 
was able to successfully prevent the incidence of autoimmune 
diabetes mellitus in NOD mice with the same dosage of LZ-8. 
This difference may be accounted for by the stronger immu­
nogenic stimulus, evoked by an allogeneic skin graft, as com­
pared with an autoimmune process. In the mouse skin al­
lograft model, previous studies have revealed that daily 
administration of CsA at 25 mg/kg caused only a modest 
increase in graft survival, with values comparable to the ones 
obtained with LZ-8. A daily high dosage of 75 mg/kg CsA was 
required for a substantial prolongation of graft survival (13).
LZ-8 provided a potent immunosuppressive effect in rat 
allogeneic islet transplantation. All rejection episodes in LZ- 
8-treated animals were delayed significantly. The most pro­
nounced effect on survival of allogeneic islets was observed in 
the group that received continuous LZ-8 infusion for over 1 
week. Normoglycemia was maintained in all animals after 
the osmotic pumps had delivered their total content.
The only observed side effect during administration of LZ-8 
was a small, albeit statistically significant, weight loss in the 
early posttransplantation days in animals that received LZ-8 
intraperitoneally on a daily or continuous basis. Kidney and 
liver functions were all in the normal range during the course 
of the experiment. The nutritional status of the animals was 
also not disturbed, as albumin and total serum protein levels 
were comparable to normal values. To be able to relate the 
immunosuppressive action of LZ-8 in this experimental set­
ting bo more well-known immunosuppressive drugs, we also 
tested the efficacy of continuous CsA administration on pro­
longation of survival time in the same model When CsA was 
administered by an osmotic minipump in the same dosage of 
6 mg/kg/day (n=6), an MST of 16.3 ±4.6 days was recorded, 
which is comparable to survival times obtained with LZ-8. 
This is also in accordance with the results of continuous 
intravenous administration of low dose CsA (2 mg/kg/day) in 
a rat cardiac allograft model, in which only a modest prolon­
gation of survival time was achieved {14). A higher dosage of 
30 mg/kg of CsA, however, was effective in inducing long­
term survival of allografted pancreatic islets in a large per­
centage of cases (15).
The immunological mechanisms, by which LZ-8 exerts its
immunosuppressive effect, need further clarification. In an 
analysis of T lymphocyte subsets in spleen and lymph nodes, 
Kino et al. (5) found an increased L3T4+ to Lyt-2+ ratio in 
NOD mice after 11 weeks of treatment with LZ-8 injections 
twice a week. CsA, also a fungal polypeptide, has immuno­
suppressive properties in common with LZ-8. CsA is equally 
effective in the prevention of the incidence of diabetes in 
NOD mice (16, 17). The modes of action of CsA and LZ-8 are, 
however, quite different. LZ-8 promotes IL-1 and IL-2 pro­
duction in vitro in the presence of human peripheral MNC, 
containing 10% macrophages (5). CsA is a potent inhibitor of 
IL-2 production at the transcription level (18). LZ-8 is 
strongly mitogenic for human peripheral MNC and mouse 
spleen cells, CsA is not mitogenic and can inhibit the mito­
genic effect of Con A (19). LZ-8 may exert its immunomodu­
latory effect by inducing quantitative and qualitative modu­
lation of adhesion molecules on immunocompetent cells (20). 
With the widespread use of CsA during the last decade, 
severe side effects of this immunosuppressive drug have been 
elucidated. The major drawbacks of CsA therapy are its 
nephrotoxicity and its toxicity toward pancreatic islets, 
which causes a diabetogenic effect (8, 9). CsA inhibits glu­
cose-induced insulin synthesis in the pancreas (21) and in­
creases peripheral insulin resistance (22). FK506 is another 
potent immunosuppressive drug, developed in 1987 from a 
Streptomyces tsukubakensis species (23). FK506 is equally as 
effective as LZ-8 or CsA in the prevention of insulitis and 
diabetes in NOD mice (24). In analysis of lymphocyte sub­
sets, only the population of L3T4+ lymphocytes was signifi­
cantly decreased by FK506 in comparison with control NOD 
mice. In contrast, the administration of LZ-8 resulted in 
overall decreased frequencies of lymphocyte subsets and an 
increased L3T4+ to Lyt-2* ratio (5). Controversy exists about 
a potential toxic effect on pancreatic islets by FK506. Kai et 
aL (24) found no harmful effects of FK506 on histological 
examination of grafted pancreatic islets in NOD mice. How­
ever, toxic effects by FK506 on pancreatic islets were de­
scribed in other studies (9} 10). Histological examination of 
FK506-treated rats revealed vacuolization and degranula­
tion of pancreatic islets (25). Also, intravenously performed 
glucose tolerance tests in an early phase after pancreas 
transplantation were compromised in cynomolgus monkeys 
that were treated with FK506 (10). These findings hamper 
the clinical use of these agents.
LZ-8 holds promise as a new immunosuppressive agent. 
Unlike other immunosuppressants, no toxicity toward pan­
creatic islets could be discerned by histological and blood 
glucose examinations, Further studies need to be performed 
to clarify exact modes of action of LZ-8, dosimetric regimens, 
and potential toxicity of LZ-8.
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